nodes	percent_of_prediction	percent_of_DWPC	metapath
Crizotinib—P-Glycoprotein Inhibitors—Cyclosporine—rheumatoid arthritis	0.367	1	CiPCiCtD
Crizotinib—PTK2B—Leflunomide—rheumatoid arthritis	0.112	0.745	CbGbCtD
Crizotinib—IRAK1—rheumatoid arthritis	0.103	0.337	CbGaD
Crizotinib—PTK2—rheumatoid arthritis	0.0874	0.287	CbGaD
Crizotinib—TYK2—rheumatoid arthritis	0.059	0.194	CbGaD
Crizotinib—BLK—rheumatoid arthritis	0.0555	0.182	CbGaD
Crizotinib—CYP3A5—Sulfasalazine—rheumatoid arthritis	0.00363	0.0242	CbGbCtD
Crizotinib—ABCB1—Methylprednisolone—rheumatoid arthritis	0.00311	0.0208	CbGbCtD
Crizotinib—CYP3A5—Hydrocortisone—rheumatoid arthritis	0.00291	0.0194	CbGbCtD
Crizotinib—CYP3A5—Cyclosporine—rheumatoid arthritis	0.00275	0.0183	CbGbCtD
Crizotinib—CYP3A4—Ergocalciferol—rheumatoid arthritis	0.00253	0.0169	CbGbCtD
Crizotinib—ACVR1—pes—rheumatoid arthritis	0.00213	0.0555	CbGeAlD
Crizotinib—ABCB1—Betamethasone—rheumatoid arthritis	0.00203	0.0135	CbGbCtD
Crizotinib—ABCB1—Prednisolone—rheumatoid arthritis	0.002	0.0133	CbGbCtD
Crizotinib—ABCB1—Hydrocortisone—rheumatoid arthritis	0.00189	0.0126	CbGbCtD
Crizotinib—ABCB1—Prednisone—rheumatoid arthritis	0.00189	0.0126	CbGbCtD
Crizotinib—CYP3A4—Methylprednisolone—rheumatoid arthritis	0.00187	0.0124	CbGbCtD
Crizotinib—CYP3A5—Dexamethasone—rheumatoid arthritis	0.00181	0.0121	CbGbCtD
Crizotinib—ABCB1—Cyclosporine—rheumatoid arthritis	0.00179	0.0119	CbGbCtD
Crizotinib—CYP3A4—Triamcinolone—rheumatoid arthritis	0.00141	0.00943	CbGbCtD
Crizotinib—CYP3A4—Betamethasone—rheumatoid arthritis	0.00121	0.00809	CbGbCtD
Crizotinib—CYP3A4—Prednisolone—rheumatoid arthritis	0.0012	0.00799	CbGbCtD
Crizotinib—ABCB1—Dexamethasone—rheumatoid arthritis	0.00118	0.00786	CbGbCtD
Crizotinib—CYP3A4—Hydrocortisone—rheumatoid arthritis	0.00113	0.00757	CbGbCtD
Crizotinib—CYP3A4—Prednisone—rheumatoid arthritis	0.00113	0.00754	CbGbCtD
Crizotinib—CYP3A4—Cyclosporine—rheumatoid arthritis	0.00107	0.00715	CbGbCtD
Crizotinib—BMP2K—synovial membrane of synovial joint—rheumatoid arthritis	0.00102	0.0265	CbGeAlD
Crizotinib—RIPK2—synovial membrane of synovial joint—rheumatoid arthritis	0.000974	0.0254	CbGeAlD
Crizotinib—ABCB1—Methotrexate—rheumatoid arthritis	0.000947	0.00631	CbGbCtD
Crizotinib—CYP3A4—Dexamethasone—rheumatoid arthritis	0.000706	0.00471	CbGbCtD
Crizotinib—ROS1—tendon—rheumatoid arthritis	0.000623	0.0162	CbGeAlD
Crizotinib—MUSK—tendon—rheumatoid arthritis	0.00053	0.0138	CbGeAlD
Crizotinib—NEK9—connective tissue—rheumatoid arthritis	0.00045	0.0117	CbGeAlD
Crizotinib—PTK2—exocrine gland—rheumatoid arthritis	0.000434	0.0113	CbGeAlD
Crizotinib—FES—parotid gland—rheumatoid arthritis	0.00041	0.0107	CbGeAlD
Crizotinib—SIK2—connective tissue—rheumatoid arthritis	0.000405	0.0106	CbGeAlD
Crizotinib—FES—saliva-secreting gland—rheumatoid arthritis	0.000393	0.0102	CbGeAlD
Crizotinib—MAPK7—connective tissue—rheumatoid arthritis	0.000365	0.00951	CbGeAlD
Crizotinib—MET—connective tissue—rheumatoid arthritis	0.000341	0.0089	CbGeAlD
Crizotinib—CDK7—connective tissue—rheumatoid arthritis	0.00033	0.00861	CbGeAlD
Crizotinib—NEK9—lymphoid tissue—rheumatoid arthritis	0.000329	0.00859	CbGeAlD
Crizotinib—NEK9—digestive system—rheumatoid arthritis	0.000325	0.00848	CbGeAlD
Crizotinib—JAK3—connective tissue—rheumatoid arthritis	0.000301	0.00785	CbGeAlD
Crizotinib—PRKD1—digestive system—rheumatoid arthritis	0.000296	0.00773	CbGeAlD
Crizotinib—STK4—connective tissue—rheumatoid arthritis	0.000295	0.0077	CbGeAlD
Crizotinib—TESK1—parotid gland—rheumatoid arthritis	0.000287	0.00747	CbGeAlD
Crizotinib—TYRO3—connective tissue—rheumatoid arthritis	0.000279	0.00728	CbGeAlD
Crizotinib—ALK—connective tissue—rheumatoid arthritis	0.000279	0.00728	CbGeAlD
Crizotinib—BLK—lymphoid tissue—rheumatoid arthritis	0.000278	0.00726	CbGeAlD
Crizotinib—LIMK1—tendon—rheumatoid arthritis	0.000278	0.00726	CbGeAlD
Crizotinib—LYN—connective tissue—rheumatoid arthritis	0.000278	0.00724	CbGeAlD
Crizotinib—TESK1—saliva-secreting gland—rheumatoid arthritis	0.000274	0.00716	CbGeAlD
Crizotinib—NUAK2—parotid gland—rheumatoid arthritis	0.000272	0.00708	CbGeAlD
Crizotinib—ACVR1—parotid gland—rheumatoid arthritis	0.00027	0.00703	CbGeAlD
Crizotinib—IGF1R—connective tissue—rheumatoid arthritis	0.000268	0.00699	CbGeAlD
Crizotinib—MAPK7—lymphoid tissue—rheumatoid arthritis	0.000267	0.00695	CbGeAlD
Crizotinib—TXK—lymphoid tissue—rheumatoid arthritis	0.000267	0.00695	CbGeAlD
Crizotinib—NUAK2—saliva-secreting gland—rheumatoid arthritis	0.00026	0.00678	CbGeAlD
Crizotinib—ACVR1—saliva-secreting gland—rheumatoid arthritis	0.000258	0.00674	CbGeAlD
Crizotinib—TESK1—connective tissue—rheumatoid arthritis	0.000252	0.00658	CbGeAlD
Crizotinib—MAPK7—tendon—rheumatoid arthritis	0.000251	0.00653	CbGeAlD
Crizotinib—MET—lymphoid tissue—rheumatoid arthritis	0.00025	0.00651	CbGeAlD
Crizotinib—FES—tendon—rheumatoid arthritis	0.000248	0.00647	CbGeAlD
Crizotinib—MET—digestive system—rheumatoid arthritis	0.000247	0.00643	CbGeAlD
Crizotinib—RIPK2—parotid gland—rheumatoid arthritis	0.000244	0.00635	CbGeAlD
Crizotinib—CDK7—lymphoid tissue—rheumatoid arthritis	0.000241	0.00629	CbGeAlD
Crizotinib—ACVR1—connective tissue—rheumatoid arthritis	0.000237	0.00619	CbGeAlD
Crizotinib—FLT3—connective tissue—rheumatoid arthritis	0.000237	0.00619	CbGeAlD
Crizotinib—MET—tendon—rheumatoid arthritis	0.000235	0.00612	CbGeAlD
Crizotinib—RIPK2—saliva-secreting gland—rheumatoid arthritis	0.000233	0.00608	CbGeAlD
Crizotinib—TBK1—parotid gland—rheumatoid arthritis	0.000226	0.0059	CbGeAlD
Crizotinib—TAOK2—tendon—rheumatoid arthritis	0.000225	0.00587	CbGeAlD
Crizotinib—TYK2—parotid gland—rheumatoid arthritis	0.000225	0.00586	CbGeAlD
Crizotinib—BMP2K—connective tissue—rheumatoid arthritis	0.000224	0.00584	CbGeAlD
Crizotinib—JAK3—lymphoid tissue—rheumatoid arthritis	0.00022	0.00574	CbGeAlD
Crizotinib—RPS6KB1—parotid gland—rheumatoid arthritis	0.000218	0.00567	CbGeAlD
Crizotinib—JAK3—digestive system—rheumatoid arthritis	0.000217	0.00567	CbGeAlD
Crizotinib—PLK4—lymphoid tissue—rheumatoid arthritis	0.000217	0.00567	CbGeAlD
Crizotinib—PTK2—saliva-secreting gland—rheumatoid arthritis	0.000217	0.00565	CbGeAlD
Crizotinib—TBK1—saliva-secreting gland—rheumatoid arthritis	0.000217	0.00565	CbGeAlD
Crizotinib—PTK2B—connective tissue—rheumatoid arthritis	0.000216	0.00564	CbGeAlD
Crizotinib—DCLK1—digestive system—rheumatoid arthritis	0.000216	0.00563	CbGeAlD
Crizotinib—STK4—lymphoid tissue—rheumatoid arthritis	0.000216	0.00563	CbGeAlD
Crizotinib—TYK2—saliva-secreting gland—rheumatoid arthritis	0.000215	0.00561	CbGeAlD
Crizotinib—RIPK2—connective tissue—rheumatoid arthritis	0.000214	0.00559	CbGeAlD
Crizotinib—STK4—digestive system—rheumatoid arthritis	0.000213	0.00556	CbGeAlD
Crizotinib—AURKA—Calcipotriol—Ergocalciferol—rheumatoid arthritis	0.00021	0.155	CbGdCrCtD
Crizotinib—RPS6KB1—saliva-secreting gland—rheumatoid arthritis	0.000208	0.00543	CbGeAlD
Crizotinib—SLK—parotid gland—rheumatoid arthritis	0.000207	0.00541	CbGeAlD
Crizotinib—EPHB4—parotid gland—rheumatoid arthritis	0.000206	0.00537	CbGeAlD
Crizotinib—DCLK1—tendon—rheumatoid arthritis	0.000206	0.00536	CbGeAlD
Crizotinib—FER—lymphoid tissue—rheumatoid arthritis	0.000204	0.00532	CbGeAlD
Crizotinib—TYRO3—lymphoid tissue—rheumatoid arthritis	0.000204	0.00532	CbGeAlD
Crizotinib—ALK—lymphoid tissue—rheumatoid arthritis	0.000204	0.00532	CbGeAlD
Crizotinib—MAP3K2—connective tissue—rheumatoid arthritis	0.000203	0.0053	CbGeAlD
Crizotinib—LYN—lymphoid tissue—rheumatoid arthritis	0.000203	0.00529	CbGeAlD
Crizotinib—EPHA2—parotid gland—rheumatoid arthritis	0.000202	0.00527	CbGeAlD
Crizotinib—EPHA5—digestive system—rheumatoid arthritis	0.000202	0.00526	CbGeAlD
Crizotinib—ALK—digestive system—rheumatoid arthritis	0.000202	0.00526	CbGeAlD
Crizotinib—MAP4K1—lymphoid tissue—rheumatoid arthritis	0.0002	0.00521	CbGeAlD
Crizotinib—PTK2—connective tissue—rheumatoid arthritis	0.000199	0.00519	CbGeAlD
Crizotinib—SLK—saliva-secreting gland—rheumatoid arthritis	0.000199	0.00518	CbGeAlD
Crizotinib—TYK2—connective tissue—rheumatoid arthritis	0.000198	0.00516	CbGeAlD
Crizotinib—EPHB4—saliva-secreting gland—rheumatoid arthritis	0.000197	0.00514	CbGeAlD
Crizotinib—MAP4K5—parotid gland—rheumatoid arthritis	0.000197	0.00514	CbGeAlD
Crizotinib—MAP3K3—parotid gland—rheumatoid arthritis	0.000197	0.00514	CbGeAlD
Crizotinib—IGF1R—lymphoid tissue—rheumatoid arthritis	0.000196	0.00511	CbGeAlD
Crizotinib—IGF1R—digestive system—rheumatoid arthritis	0.000194	0.00505	CbGeAlD
Crizotinib—EPHA2—saliva-secreting gland—rheumatoid arthritis	0.000193	0.00504	CbGeAlD
Crizotinib—MAP4K2—lymphoid tissue—rheumatoid arthritis	0.000193	0.00504	CbGeAlD
Crizotinib—FER—tendon—rheumatoid arthritis	0.000192	0.005	CbGeAlD
Crizotinib—RPS6KB1—connective tissue—rheumatoid arthritis	0.000192	0.00499	CbGeAlD
Crizotinib—TNK1—tendon—rheumatoid arthritis	0.00019	0.00495	CbGeAlD
Crizotinib—AXL—connective tissue—rheumatoid arthritis	0.00019	0.00494	CbGeAlD
Crizotinib—MAP4K5—saliva-secreting gland—rheumatoid arthritis	0.000189	0.00492	CbGeAlD
Crizotinib—MAP3K3—saliva-secreting gland—rheumatoid arthritis	0.000189	0.00492	CbGeAlD
Crizotinib—EPHB6—parotid gland—rheumatoid arthritis	0.000188	0.00491	CbGeAlD
Crizotinib—MAP4K1—tendon—rheumatoid arthritis	0.000188	0.0049	CbGeAlD
Crizotinib—AURKA—lymphoid tissue—rheumatoid arthritis	0.000186	0.00485	CbGeAlD
Crizotinib—AURKA—digestive system—rheumatoid arthritis	0.000184	0.00479	CbGeAlD
Crizotinib—YES1—parotid gland—rheumatoid arthritis	0.000182	0.00474	CbGeAlD
Crizotinib—MAP4K2—tendon—rheumatoid arthritis	0.000182	0.00474	CbGeAlD
Crizotinib—EPHB4—connective tissue—rheumatoid arthritis	0.000181	0.00472	CbGeAlD
Crizotinib—EPHB6—saliva-secreting gland—rheumatoid arthritis	0.00018	0.0047	CbGeAlD
Crizotinib—JAK2—connective tissue—rheumatoid arthritis	0.00018	0.00469	CbGeAlD
Crizotinib—TAOK3—parotid gland—rheumatoid arthritis	0.00018	0.00468	CbGeAlD
Crizotinib—MERTK—lymphoid tissue—rheumatoid arthritis	0.000179	0.00468	CbGeAlD
Crizotinib—STK3—tendon—rheumatoid arthritis	0.000179	0.00468	CbGeAlD
Crizotinib—LIMK2—lymphoid tissue—rheumatoid arthritis	0.000175	0.00457	CbGeAlD
Crizotinib—AURKA—tendon—rheumatoid arthritis	0.000175	0.00456	CbGeAlD
Crizotinib—YES1—saliva-secreting gland—rheumatoid arthritis	0.000174	0.00454	CbGeAlD
Crizotinib—FLT3—lymphoid tissue—rheumatoid arthritis	0.000174	0.00453	CbGeAlD
Crizotinib—TEK—connective tissue—rheumatoid arthritis	0.000173	0.00452	CbGeAlD
Crizotinib—TESK1—tendon—rheumatoid arthritis	0.000173	0.00452	CbGeAlD
Crizotinib—TAOK3—saliva-secreting gland—rheumatoid arthritis	0.000172	0.00449	CbGeAlD
Crizotinib—MERTK—tendon—rheumatoid arthritis	0.000169	0.0044	CbGeAlD
Crizotinib—ACVR1—tendon—rheumatoid arthritis	0.000163	0.00425	CbGeAlD
Crizotinib—MAP3K12—tendon—rheumatoid arthritis	0.000163	0.00425	CbGeAlD
Crizotinib—YES1—connective tissue—rheumatoid arthritis	0.00016	0.00418	CbGeAlD
Crizotinib—STK35—tendon—rheumatoid arthritis	0.00016	0.00417	CbGeAlD
Crizotinib—PTK2B—lymphoid tissue—rheumatoid arthritis	0.000158	0.00412	CbGeAlD
Crizotinib—TAOK3—connective tissue—rheumatoid arthritis	0.000158	0.00412	CbGeAlD
Crizotinib—PTK2B—digestive system—rheumatoid arthritis	0.000156	0.00407	CbGeAlD
Crizotinib—ABL2—tendon—rheumatoid arthritis	0.000156	0.00406	CbGeAlD
Crizotinib—RIPK2—digestive system—rheumatoid arthritis	0.000155	0.00404	CbGeAlD
Crizotinib—SRC—connective tissue—rheumatoid arthritis	0.000154	0.00402	CbGeAlD
Crizotinib—BMP2K—tendon—rheumatoid arthritis	0.000154	0.00401	CbGeAlD
Crizotinib—MAP3K2—lymphoid tissue—rheumatoid arthritis	0.000149	0.00388	CbGeAlD
Crizotinib—PTK2B—tendon—rheumatoid arthritis	0.000149	0.00387	CbGeAlD
Crizotinib—RIPK2—tendon—rheumatoid arthritis	0.000147	0.00384	CbGeAlD
Crizotinib—PTK2—lymphoid tissue—rheumatoid arthritis	0.000146	0.0038	CbGeAlD
Crizotinib—TBK1—lymphoid tissue—rheumatoid arthritis	0.000146	0.0038	CbGeAlD
Crizotinib—TYK2—lymphoid tissue—rheumatoid arthritis	0.000145	0.00377	CbGeAlD
Crizotinib—TBK1—digestive system—rheumatoid arthritis	0.000144	0.00375	CbGeAlD
Crizotinib—PTK2—digestive system—rheumatoid arthritis	0.000144	0.00375	CbGeAlD
Crizotinib—TYK2—digestive system—rheumatoid arthritis	0.000143	0.00372	CbGeAlD
Crizotinib—EPHA4—tendon—rheumatoid arthritis	0.000142	0.00371	CbGeAlD
Crizotinib—RPS6KB1—lymphoid tissue—rheumatoid arthritis	0.00014	0.00365	CbGeAlD
Crizotinib—FGR—lymphoid tissue—rheumatoid arthritis	0.000139	0.00363	CbGeAlD
Crizotinib—AXL—lymphoid tissue—rheumatoid arthritis	0.000139	0.00361	CbGeAlD
Crizotinib—RPS6KB1—digestive system—rheumatoid arthritis	0.000138	0.00361	CbGeAlD
Crizotinib—CSF1R—connective tissue—rheumatoid arthritis	0.000138	0.00361	CbGeAlD
Crizotinib—FGR—digestive system—rheumatoid arthritis	0.000137	0.00358	CbGeAlD
Crizotinib—PTK2—tendon—rheumatoid arthritis	0.000137	0.00357	CbGeAlD
Crizotinib—TBK1—tendon—rheumatoid arthritis	0.000137	0.00357	CbGeAlD
Crizotinib—TYK2—tendon—rheumatoid arthritis	0.000136	0.00354	CbGeAlD
Crizotinib—IRAK1—tendon—rheumatoid arthritis	0.000134	0.0035	CbGeAlD
Crizotinib—RPS6KB1—tendon—rheumatoid arthritis	0.000132	0.00343	CbGeAlD
Crizotinib—JAK2—lymphoid tissue—rheumatoid arthritis	0.000132	0.00343	CbGeAlD
Crizotinib—EPHB4—digestive system—rheumatoid arthritis	0.000131	0.00341	CbGeAlD
Crizotinib—FGR—tendon—rheumatoid arthritis	0.000131	0.00341	CbGeAlD
Crizotinib—AXL—tendon—rheumatoid arthritis	0.00013	0.0034	CbGeAlD
Crizotinib—EPHA2—lymphoid tissue—rheumatoid arthritis	0.00013	0.00339	CbGeAlD
Crizotinib—JAK2—digestive system—rheumatoid arthritis	0.00013	0.00339	CbGeAlD
Crizotinib—EPHA2—digestive system—rheumatoid arthritis	0.000128	0.00335	CbGeAlD
Crizotinib—MAP4K5—lymphoid tissue—rheumatoid arthritis	0.000127	0.00331	CbGeAlD
Crizotinib—TEK—lymphoid tissue—rheumatoid arthritis	0.000127	0.00331	CbGeAlD
Crizotinib—SLK—tendon—rheumatoid arthritis	0.000125	0.00327	CbGeAlD
Crizotinib—EPHB4—tendon—rheumatoid arthritis	0.000125	0.00325	CbGeAlD
Crizotinib—ABL1—parotid gland—rheumatoid arthritis	0.000124	0.00324	CbGeAlD
Crizotinib—JAK2—tendon—rheumatoid arthritis	0.000124	0.00322	CbGeAlD
Crizotinib—EPHA2—tendon—rheumatoid arthritis	0.000122	0.00319	CbGeAlD
Crizotinib—MAP4K5—tendon—rheumatoid arthritis	0.000119	0.00311	CbGeAlD
Crizotinib—MAP3K3—tendon—rheumatoid arthritis	0.000119	0.00311	CbGeAlD
Crizotinib—TEK—tendon—rheumatoid arthritis	0.000119	0.00311	CbGeAlD
Crizotinib—ABL1—saliva-secreting gland—rheumatoid arthritis	0.000119	0.0031	CbGeAlD
Crizotinib—YES1—lymphoid tissue—rheumatoid arthritis	0.000117	0.00305	CbGeAlD
Crizotinib—STK10—lymphoid tissue—rheumatoid arthritis	0.000116	0.00303	CbGeAlD
Crizotinib—YES1—digestive system—rheumatoid arthritis	0.000116	0.00302	CbGeAlD
Crizotinib—TAOK3—lymphoid tissue—rheumatoid arthritis	0.000116	0.00301	CbGeAlD
Crizotinib—STK10—digestive system—rheumatoid arthritis	0.000115	0.00299	CbGeAlD
Crizotinib—TAOK3—digestive system—rheumatoid arthritis	0.000114	0.00298	CbGeAlD
Crizotinib—EPHB6—tendon—rheumatoid arthritis	0.000114	0.00297	CbGeAlD
Crizotinib—SRC—lymphoid tissue—rheumatoid arthritis	0.000113	0.00294	CbGeAlD
Crizotinib—SRC—digestive system—rheumatoid arthritis	0.000111	0.0029	CbGeAlD
Crizotinib—YES1—tendon—rheumatoid arthritis	0.00011	0.00287	CbGeAlD
Crizotinib—ABL1—connective tissue—rheumatoid arthritis	0.000109	0.00285	CbGeAlD
Crizotinib—STK10—tendon—rheumatoid arthritis	0.000109	0.00284	CbGeAlD
Crizotinib—TAOK3—tendon—rheumatoid arthritis	0.000109	0.00283	CbGeAlD
Crizotinib—CSF1R—lymphoid tissue—rheumatoid arthritis	0.000101	0.00264	CbGeAlD
Crizotinib—CSF1R—digestive system—rheumatoid arthritis	9.99e-05	0.0026	CbGeAlD
Crizotinib—CSF1R—tendon—rheumatoid arthritis	9.51e-05	0.00248	CbGeAlD
Crizotinib—ABL1—lymphoid tissue—rheumatoid arthritis	7.99e-05	0.00208	CbGeAlD
Crizotinib—ABL1—digestive system—rheumatoid arthritis	7.9e-05	0.00206	CbGeAlD
Crizotinib—Mediastinal disorder—Cyclosporine—rheumatoid arthritis	7.56e-05	0.00181	CcSEcCtD
Crizotinib—ABL1—tendon—rheumatoid arthritis	7.52e-05	0.00196	CbGeAlD
Crizotinib—Skin disorder—Leflunomide—rheumatoid arthritis	7.5e-05	0.0018	CcSEcCtD
Crizotinib—Arrhythmia—Cyclosporine—rheumatoid arthritis	7.49e-05	0.00179	CcSEcCtD
Crizotinib—Hepatic failure—Methotrexate—rheumatoid arthritis	7.45e-05	0.00179	CcSEcCtD
Crizotinib—Visual impairment—Prednisolone—rheumatoid arthritis	7.35e-05	0.00176	CcSEcCtD
Crizotinib—Malnutrition—Cyclosporine—rheumatoid arthritis	7.3e-05	0.00175	CcSEcCtD
Crizotinib—Hypokalaemia—Prednisone—rheumatoid arthritis	7.3e-05	0.00175	CcSEcCtD
Crizotinib—Weight decreased—Dexamethasone—rheumatoid arthritis	7.2e-05	0.00172	CcSEcCtD
Crizotinib—Weight decreased—Betamethasone—rheumatoid arthritis	7.2e-05	0.00172	CcSEcCtD
Crizotinib—Dysgeusia—Cyclosporine—rheumatoid arthritis	7.15e-05	0.00171	CcSEcCtD
Crizotinib—Bradycardia—Triamcinolone—rheumatoid arthritis	7.14e-05	0.00171	CcSEcCtD
Crizotinib—Bradycardia—Methylprednisolone—rheumatoid arthritis	7.13e-05	0.00171	CcSEcCtD
Crizotinib—Muscular weakness—Prednisone—rheumatoid arthritis	7.07e-05	0.00169	CcSEcCtD
Crizotinib—Alanine aminotransferase increased—Prednisone—rheumatoid arthritis	7.07e-05	0.00169	CcSEcCtD
Crizotinib—Visual disturbance—Methotrexate—rheumatoid arthritis	7.07e-05	0.00169	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Azathioprine—rheumatoid arthritis	7.06e-05	0.00169	CcSEcCtD
Crizotinib—Eye disorder—Hydrocortisone—rheumatoid arthritis	6.97e-05	0.00167	CcSEcCtD
Crizotinib—Neuropathy peripheral—Betamethasone—rheumatoid arthritis	6.95e-05	0.00167	CcSEcCtD
Crizotinib—Neuropathy peripheral—Dexamethasone—rheumatoid arthritis	6.95e-05	0.00167	CcSEcCtD
Crizotinib—Paraesthesia—Leflunomide—rheumatoid arthritis	6.93e-05	0.00166	CcSEcCtD
Crizotinib—Dyspnoea—Leflunomide—rheumatoid arthritis	6.88e-05	0.00165	CcSEcCtD
Crizotinib—Vision blurred—Cyclosporine—rheumatoid arthritis	6.88e-05	0.00165	CcSEcCtD
Crizotinib—Arrhythmia—Prednisolone—rheumatoid arthritis	6.82e-05	0.00163	CcSEcCtD
Crizotinib—Dyspepsia—Leflunomide—rheumatoid arthritis	6.8e-05	0.00163	CcSEcCtD
Crizotinib—Visual impairment—Methylprednisolone—rheumatoid arthritis	6.75e-05	0.00162	CcSEcCtD
Crizotinib—Anaemia—Cyclosporine—rheumatoid arthritis	6.75e-05	0.00162	CcSEcCtD
Crizotinib—Decreased appetite—Leflunomide—rheumatoid arthritis	6.71e-05	0.00161	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Leflunomide—rheumatoid arthritis	6.67e-05	0.0016	CcSEcCtD
Crizotinib—Arrhythmia—Hydrocortisone—rheumatoid arthritis	6.66e-05	0.0016	CcSEcCtD
Crizotinib—Fatigue—Leflunomide—rheumatoid arthritis	6.66e-05	0.00159	CcSEcCtD
Crizotinib—Constipation—Leflunomide—rheumatoid arthritis	6.6e-05	0.00158	CcSEcCtD
Crizotinib—Eye disorder—Methylprednisolone—rheumatoid arthritis	6.54e-05	0.00157	CcSEcCtD
Crizotinib—Leukopenia—Cyclosporine—rheumatoid arthritis	6.53e-05	0.00157	CcSEcCtD
Crizotinib—Cardiac disorder—Methylprednisolone—rheumatoid arthritis	6.5e-05	0.00156	CcSEcCtD
Crizotinib—Malnutrition—Hydrocortisone—rheumatoid arthritis	6.49e-05	0.00155	CcSEcCtD
Crizotinib—Bradycardia—Dexamethasone—rheumatoid arthritis	6.48e-05	0.00155	CcSEcCtD
Crizotinib—Bradycardia—Betamethasone—rheumatoid arthritis	6.48e-05	0.00155	CcSEcCtD
Crizotinib—Neutropenia—Prednisone—rheumatoid arthritis	6.48e-05	0.00155	CcSEcCtD
Crizotinib—Body temperature increased—Azathioprine—rheumatoid arthritis	6.46e-05	0.00155	CcSEcCtD
Crizotinib—ACVR1—Betamethasone—Hydrocortisone—rheumatoid arthritis	6.33e-05	0.0468	CbGdCrCtD
Crizotinib—ACVR1—Dexamethasone—Hydrocortisone—rheumatoid arthritis	6.33e-05	0.0468	CbGdCrCtD
Crizotinib—Mediastinal disorder—Methylprednisolone—rheumatoid arthritis	6.31e-05	0.00151	CcSEcCtD
Crizotinib—Arrhythmia—Triamcinolone—rheumatoid arthritis	6.27e-05	0.0015	CcSEcCtD
Crizotinib—Weight decreased—Prednisone—rheumatoid arthritis	6.27e-05	0.0015	CcSEcCtD
Crizotinib—Vision blurred—Prednisolone—rheumatoid arthritis	6.26e-05	0.0015	CcSEcCtD
Crizotinib—Arrhythmia—Methylprednisolone—rheumatoid arthritis	6.26e-05	0.0015	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Cyclosporine—rheumatoid arthritis	6.17e-05	0.00148	CcSEcCtD
Crizotinib—Visual impairment—Dexamethasone—rheumatoid arthritis	6.14e-05	0.00147	CcSEcCtD
Crizotinib—Visual impairment—Betamethasone—rheumatoid arthritis	6.14e-05	0.00147	CcSEcCtD
Crizotinib—Body temperature increased—Leflunomide—rheumatoid arthritis	6.1e-05	0.00146	CcSEcCtD
Crizotinib—Malnutrition—Methylprednisolone—rheumatoid arthritis	6.1e-05	0.00146	CcSEcCtD
Crizotinib—Neuropathy peripheral—Prednisone—rheumatoid arthritis	6.06e-05	0.00145	CcSEcCtD
Crizotinib—Dysgeusia—Triamcinolone—rheumatoid arthritis	5.98e-05	0.00143	CcSEcCtD
Crizotinib—ACVR1—Betamethasone—Methylprednisolone—rheumatoid arthritis	5.97e-05	0.0442	CbGdCrCtD
Crizotinib—ACVR1—Dexamethasone—Methylprednisolone—rheumatoid arthritis	5.97e-05	0.0442	CbGdCrCtD
Crizotinib—Oedema—Cyclosporine—rheumatoid arthritis	5.96e-05	0.00143	CcSEcCtD
Crizotinib—Syncope—Prednisolone—rheumatoid arthritis	5.96e-05	0.00143	CcSEcCtD
Crizotinib—Eye disorder—Betamethasone—rheumatoid arthritis	5.95e-05	0.00143	CcSEcCtD
Crizotinib—Eye disorder—Dexamethasone—rheumatoid arthritis	5.95e-05	0.00143	CcSEcCtD
Crizotinib—Infection—Cyclosporine—rheumatoid arthritis	5.92e-05	0.00142	CcSEcCtD
Crizotinib—ACVR1—Dexamethasone—Betamethasone—rheumatoid arthritis	5.88e-05	0.0435	CbGdCrCtD
Crizotinib—ACVR1—Betamethasone—Dexamethasone—rheumatoid arthritis	5.88e-05	0.0435	CbGdCrCtD
Crizotinib—Nervous system disorder—Cyclosporine—rheumatoid arthritis	5.84e-05	0.0014	CcSEcCtD
Crizotinib—Loss of consciousness—Prednisolone—rheumatoid arthritis	5.84e-05	0.0014	CcSEcCtD
Crizotinib—Syncope—Hydrocortisone—rheumatoid arthritis	5.82e-05	0.00139	CcSEcCtD
Crizotinib—Skin disorder—Cyclosporine—rheumatoid arthritis	5.79e-05	0.00139	CcSEcCtD
Crizotinib—ACVR1—Dexamethasone—Triamcinolone—rheumatoid arthritis	5.74e-05	0.0425	CbGdCrCtD
Crizotinib—ACVR1—Betamethasone—Triamcinolone—rheumatoid arthritis	5.74e-05	0.0425	CbGdCrCtD
Crizotinib—Loss of consciousness—Hydrocortisone—rheumatoid arthritis	5.7e-05	0.00137	CcSEcCtD
Crizotinib—Arrhythmia—Dexamethasone—rheumatoid arthritis	5.69e-05	0.00136	CcSEcCtD
Crizotinib—Arrhythmia—Betamethasone—rheumatoid arthritis	5.69e-05	0.00136	CcSEcCtD
Crizotinib—Bradycardia—Prednisone—rheumatoid arthritis	5.65e-05	0.00135	CcSEcCtD
Crizotinib—Diarrhoea—Azathioprine—rheumatoid arthritis	5.59e-05	0.00134	CcSEcCtD
Crizotinib—Asthenia—Leflunomide—rheumatoid arthritis	5.54e-05	0.00133	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Hydrocortisone—rheumatoid arthritis	5.49e-05	0.00131	CcSEcCtD
Crizotinib—Syncope—Triamcinolone—rheumatoid arthritis	5.48e-05	0.00131	CcSEcCtD
Crizotinib—Syncope—Methylprednisolone—rheumatoid arthritis	5.47e-05	0.00131	CcSEcCtD
Crizotinib—ACVR1—Betamethasone—Prednisone—rheumatoid arthritis	5.45e-05	0.0403	CbGdCrCtD
Crizotinib—ACVR1—Dexamethasone—Prednisone—rheumatoid arthritis	5.45e-05	0.0403	CbGdCrCtD
Crizotinib—Oedema—Prednisolone—rheumatoid arthritis	5.42e-05	0.0013	CcSEcCtD
Crizotinib—Neutropenia—Methotrexate—rheumatoid arthritis	5.41e-05	0.0013	CcSEcCtD
Crizotinib—Dizziness—Azathioprine—rheumatoid arthritis	5.41e-05	0.0013	CcSEcCtD
Crizotinib—Upper respiratory tract infection—Methotrexate—rheumatoid arthritis	5.38e-05	0.00129	CcSEcCtD
Crizotinib—Loss of consciousness—Triamcinolone—rheumatoid arthritis	5.37e-05	0.00129	CcSEcCtD
Crizotinib—Loss of consciousness—Methylprednisolone—rheumatoid arthritis	5.36e-05	0.00128	CcSEcCtD
Crizotinib—Paraesthesia—Cyclosporine—rheumatoid arthritis	5.35e-05	0.00128	CcSEcCtD
Crizotinib—Shock—Prednisolone—rheumatoid arthritis	5.33e-05	0.00128	CcSEcCtD
Crizotinib—ACVR1—Dexamethasone—Prednisolone—rheumatoid arthritis	5.32e-05	0.0394	CbGdCrCtD
Crizotinib—ACVR1—Betamethasone—Prednisolone—rheumatoid arthritis	5.32e-05	0.0394	CbGdCrCtD
Crizotinib—Dyspnoea—Cyclosporine—rheumatoid arthritis	5.31e-05	0.00127	CcSEcCtD
Crizotinib—Oedema—Hydrocortisone—rheumatoid arthritis	5.3e-05	0.00127	CcSEcCtD
Crizotinib—Diarrhoea—Leflunomide—rheumatoid arthritis	5.28e-05	0.00127	CcSEcCtD
Crizotinib—Infection—Hydrocortisone—rheumatoid arthritis	5.26e-05	0.00126	CcSEcCtD
Crizotinib—Dyspepsia—Cyclosporine—rheumatoid arthritis	5.24e-05	0.00126	CcSEcCtD
Crizotinib—Shock—Hydrocortisone—rheumatoid arthritis	5.21e-05	0.00125	CcSEcCtD
Crizotinib—Vomiting—Azathioprine—rheumatoid arthritis	5.2e-05	0.00125	CcSEcCtD
Crizotinib—Nervous system disorder—Hydrocortisone—rheumatoid arthritis	5.19e-05	0.00124	CcSEcCtD
Crizotinib—Pneumonia—Methotrexate—rheumatoid arthritis	5.19e-05	0.00124	CcSEcCtD
Crizotinib—Eye disorder—Prednisone—rheumatoid arthritis	5.18e-05	0.00124	CcSEcCtD
Crizotinib—Decreased appetite—Cyclosporine—rheumatoid arthritis	5.18e-05	0.00124	CcSEcCtD
Crizotinib—Infestation—Methotrexate—rheumatoid arthritis	5.16e-05	0.00124	CcSEcCtD
Crizotinib—Infestation NOS—Methotrexate—rheumatoid arthritis	5.16e-05	0.00124	CcSEcCtD
Crizotinib—Rash—Azathioprine—rheumatoid arthritis	5.15e-05	0.00123	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—rheumatoid arthritis	5.15e-05	0.00123	CcSEcCtD
Crizotinib—Dermatitis—Azathioprine—rheumatoid arthritis	5.15e-05	0.00123	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Cyclosporine—rheumatoid arthritis	5.14e-05	0.00123	CcSEcCtD
Crizotinib—Skin disorder—Hydrocortisone—rheumatoid arthritis	5.14e-05	0.00123	CcSEcCtD
Crizotinib—Fatigue—Cyclosporine—rheumatoid arthritis	5.14e-05	0.00123	CcSEcCtD
Crizotinib—Dizziness—Leflunomide—rheumatoid arthritis	5.11e-05	0.00122	CcSEcCtD
Crizotinib—Constipation—Cyclosporine—rheumatoid arthritis	5.1e-05	0.00122	CcSEcCtD
Crizotinib—Oedema—Triamcinolone—rheumatoid arthritis	4.99e-05	0.00119	CcSEcCtD
Crizotinib—Syncope—Dexamethasone—rheumatoid arthritis	4.97e-05	0.00119	CcSEcCtD
Crizotinib—Syncope—Betamethasone—rheumatoid arthritis	4.97e-05	0.00119	CcSEcCtD
Crizotinib—Arrhythmia—Prednisone—rheumatoid arthritis	4.95e-05	0.00119	CcSEcCtD
Crizotinib—Infection—Triamcinolone—rheumatoid arthritis	4.95e-05	0.00119	CcSEcCtD
Crizotinib—Infection—Methylprednisolone—rheumatoid arthritis	4.94e-05	0.00118	CcSEcCtD
Crizotinib—Vomiting—Leflunomide—rheumatoid arthritis	4.91e-05	0.00118	CcSEcCtD
Crizotinib—Shock—Triamcinolone—rheumatoid arthritis	4.91e-05	0.00118	CcSEcCtD
Crizotinib—Shock—Methylprednisolone—rheumatoid arthritis	4.89e-05	0.00117	CcSEcCtD
Crizotinib—Hepatobiliary disease—Methotrexate—rheumatoid arthritis	4.88e-05	0.00117	CcSEcCtD
Crizotinib—Nervous system disorder—Methylprednisolone—rheumatoid arthritis	4.88e-05	0.00117	CcSEcCtD
Crizotinib—Loss of consciousness—Betamethasone—rheumatoid arthritis	4.87e-05	0.00117	CcSEcCtD
Crizotinib—Loss of consciousness—Dexamethasone—rheumatoid arthritis	4.87e-05	0.00117	CcSEcCtD
Crizotinib—Paraesthesia—Prednisolone—rheumatoid arthritis	4.87e-05	0.00117	CcSEcCtD
Crizotinib—Rash—Leflunomide—rheumatoid arthritis	4.87e-05	0.00117	CcSEcCtD
Crizotinib—Dermatitis—Leflunomide—rheumatoid arthritis	4.86e-05	0.00117	CcSEcCtD
Crizotinib—Nausea—Azathioprine—rheumatoid arthritis	4.86e-05	0.00116	CcSEcCtD
Crizotinib—Skin disorder—Methylprednisolone—rheumatoid arthritis	4.83e-05	0.00116	CcSEcCtD
Crizotinib—Malnutrition—Prednisone—rheumatoid arthritis	4.83e-05	0.00116	CcSEcCtD
Crizotinib—Paraesthesia—Hydrocortisone—rheumatoid arthritis	4.75e-05	0.00114	CcSEcCtD
Crizotinib—Body temperature increased—Cyclosporine—rheumatoid arthritis	4.71e-05	0.00113	CcSEcCtD
Crizotinib—Dyspepsia—Hydrocortisone—rheumatoid arthritis	4.66e-05	0.00112	CcSEcCtD
Crizotinib—CYP3A5—digestive system—rheumatoid arthritis	4.62e-05	0.00121	CbGeAlD
Crizotinib—Decreased appetite—Hydrocortisone—rheumatoid arthritis	4.6e-05	0.0011	CcSEcCtD
Crizotinib—Nausea—Leflunomide—rheumatoid arthritis	4.59e-05	0.0011	CcSEcCtD
Crizotinib—Urinary tract disorder—Methotrexate—rheumatoid arthritis	4.58e-05	0.0011	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Hydrocortisone—rheumatoid arthritis	4.57e-05	0.0011	CcSEcCtD
Crizotinib—Fatigue—Hydrocortisone—rheumatoid arthritis	4.57e-05	0.00109	CcSEcCtD
Crizotinib—Vision blurred—Prednisone—rheumatoid arthritis	4.55e-05	0.00109	CcSEcCtD
Crizotinib—Urethral disorder—Methotrexate—rheumatoid arthritis	4.54e-05	0.00109	CcSEcCtD
Crizotinib—Oedema—Betamethasone—rheumatoid arthritis	4.52e-05	0.00108	CcSEcCtD
Crizotinib—Oedema—Dexamethasone—rheumatoid arthritis	4.52e-05	0.00108	CcSEcCtD
Crizotinib—Infection—Betamethasone—rheumatoid arthritis	4.49e-05	0.00108	CcSEcCtD
Crizotinib—Infection—Dexamethasone—rheumatoid arthritis	4.49e-05	0.00108	CcSEcCtD
Crizotinib—Paraesthesia—Triamcinolone—rheumatoid arthritis	4.48e-05	0.00107	CcSEcCtD
Crizotinib—Paraesthesia—Methylprednisolone—rheumatoid arthritis	4.47e-05	0.00107	CcSEcCtD
Crizotinib—Visual impairment—Methotrexate—rheumatoid arthritis	4.47e-05	0.00107	CcSEcCtD
Crizotinib—Anaemia—Prednisone—rheumatoid arthritis	4.46e-05	0.00107	CcSEcCtD
Crizotinib—Shock—Betamethasone—rheumatoid arthritis	4.45e-05	0.00107	CcSEcCtD
Crizotinib—Shock—Dexamethasone—rheumatoid arthritis	4.45e-05	0.00107	CcSEcCtD
Crizotinib—Dyspnoea—Triamcinolone—rheumatoid arthritis	4.45e-05	0.00106	CcSEcCtD
Crizotinib—Nervous system disorder—Betamethasone—rheumatoid arthritis	4.44e-05	0.00106	CcSEcCtD
Crizotinib—Nervous system disorder—Dexamethasone—rheumatoid arthritis	4.44e-05	0.00106	CcSEcCtD
Crizotinib—Dyspepsia—Triamcinolone—rheumatoid arthritis	4.39e-05	0.00105	CcSEcCtD
Crizotinib—Dyspepsia—Methylprednisolone—rheumatoid arthritis	4.38e-05	0.00105	CcSEcCtD
Crizotinib—Eye disorder—Methotrexate—rheumatoid arthritis	4.33e-05	0.00104	CcSEcCtD
Crizotinib—Syncope—Prednisone—rheumatoid arthritis	4.33e-05	0.00104	CcSEcCtD
Crizotinib—Cardiac disorder—Methotrexate—rheumatoid arthritis	4.3e-05	0.00103	CcSEcCtD
Crizotinib—Fatigue—Triamcinolone—rheumatoid arthritis	4.3e-05	0.00103	CcSEcCtD
Crizotinib—Fatigue—Methylprednisolone—rheumatoid arthritis	4.29e-05	0.00103	CcSEcCtD
Crizotinib—Asthenia—Cyclosporine—rheumatoid arthritis	4.27e-05	0.00102	CcSEcCtD
Crizotinib—Loss of consciousness—Prednisone—rheumatoid arthritis	4.24e-05	0.00102	CcSEcCtD
Crizotinib—Body temperature increased—Hydrocortisone—rheumatoid arthritis	4.19e-05	0.001	CcSEcCtD
Crizotinib—Mediastinal disorder—Methotrexate—rheumatoid arthritis	4.18e-05	0.001	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—rheumatoid arthritis	4.08e-05	0.000978	CcSEcCtD
Crizotinib—TESK1—Betamethasone—Hydrocortisone—rheumatoid arthritis	4.08e-05	0.0302	CbGdCrCtD
Crizotinib—TESK1—Dexamethasone—Hydrocortisone—rheumatoid arthritis	4.08e-05	0.0302	CbGdCrCtD
Crizotinib—Diarrhoea—Cyclosporine—rheumatoid arthritis	4.08e-05	0.000977	CcSEcCtD
Crizotinib—Paraesthesia—Dexamethasone—rheumatoid arthritis	4.06e-05	0.000973	CcSEcCtD
Crizotinib—Paraesthesia—Betamethasone—rheumatoid arthritis	4.06e-05	0.000973	CcSEcCtD
Crizotinib—Malnutrition—Methotrexate—rheumatoid arthritis	4.03e-05	0.000966	CcSEcCtD
Crizotinib—Dyspepsia—Dexamethasone—rheumatoid arthritis	3.98e-05	0.000954	CcSEcCtD
Crizotinib—Dyspepsia—Betamethasone—rheumatoid arthritis	3.98e-05	0.000954	CcSEcCtD
Crizotinib—Dysgeusia—Methotrexate—rheumatoid arthritis	3.95e-05	0.000946	CcSEcCtD
Crizotinib—Body temperature increased—Triamcinolone—rheumatoid arthritis	3.94e-05	0.000944	CcSEcCtD
Crizotinib—Dizziness—Cyclosporine—rheumatoid arthritis	3.94e-05	0.000944	CcSEcCtD
Crizotinib—Oedema—Prednisone—rheumatoid arthritis	3.94e-05	0.000944	CcSEcCtD
Crizotinib—Decreased appetite—Dexamethasone—rheumatoid arthritis	3.93e-05	0.000942	CcSEcCtD
Crizotinib—Decreased appetite—Betamethasone—rheumatoid arthritis	3.93e-05	0.000942	CcSEcCtD
Crizotinib—Infection—Prednisone—rheumatoid arthritis	3.91e-05	0.000938	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Betamethasone—rheumatoid arthritis	3.91e-05	0.000936	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Dexamethasone—rheumatoid arthritis	3.91e-05	0.000936	CcSEcCtD
Crizotinib—Fatigue—Betamethasone—rheumatoid arthritis	3.9e-05	0.000934	CcSEcCtD
Crizotinib—Fatigue—Dexamethasone—rheumatoid arthritis	3.9e-05	0.000934	CcSEcCtD
Crizotinib—Shock—Prednisone—rheumatoid arthritis	3.88e-05	0.000929	CcSEcCtD
Crizotinib—Nervous system disorder—Prednisone—rheumatoid arthritis	3.86e-05	0.000926	CcSEcCtD
Crizotinib—TESK1—Betamethasone—Methylprednisolone—rheumatoid arthritis	3.85e-05	0.0285	CbGdCrCtD
Crizotinib—TESK1—Dexamethasone—Methylprednisolone—rheumatoid arthritis	3.85e-05	0.0285	CbGdCrCtD
Crizotinib—Skin disorder—Prednisone—rheumatoid arthritis	3.83e-05	0.000917	CcSEcCtD
Crizotinib—Vision blurred—Methotrexate—rheumatoid arthritis	3.8e-05	0.000911	CcSEcCtD
Crizotinib—Asthenia—Hydrocortisone—rheumatoid arthritis	3.8e-05	0.00091	CcSEcCtD
Crizotinib—Vomiting—Cyclosporine—rheumatoid arthritis	3.79e-05	0.000908	CcSEcCtD
Crizotinib—TESK1—Betamethasone—Dexamethasone—rheumatoid arthritis	3.79e-05	0.028	CbGdCrCtD
Crizotinib—TESK1—Dexamethasone—Betamethasone—rheumatoid arthritis	3.79e-05	0.028	CbGdCrCtD
Crizotinib—Rash—Cyclosporine—rheumatoid arthritis	3.76e-05	0.0009	CcSEcCtD
Crizotinib—Dermatitis—Cyclosporine—rheumatoid arthritis	3.75e-05	0.000899	CcSEcCtD
Crizotinib—Anaemia—Methotrexate—rheumatoid arthritis	3.73e-05	0.000893	CcSEcCtD
Crizotinib—TESK1—Dexamethasone—Triamcinolone—rheumatoid arthritis	3.7e-05	0.0274	CbGdCrCtD
Crizotinib—TESK1—Betamethasone—Triamcinolone—rheumatoid arthritis	3.7e-05	0.0274	CbGdCrCtD
Crizotinib—Diarrhoea—Hydrocortisone—rheumatoid arthritis	3.62e-05	0.000868	CcSEcCtD
Crizotinib—Leukopenia—Methotrexate—rheumatoid arthritis	3.61e-05	0.000865	CcSEcCtD
Crizotinib—Dizziness—Prednisolone—rheumatoid arthritis	3.59e-05	0.000859	CcSEcCtD
Crizotinib—Asthenia—Triamcinolone—rheumatoid arthritis	3.58e-05	0.000857	CcSEcCtD
Crizotinib—Body temperature increased—Betamethasone—rheumatoid arthritis	3.58e-05	0.000857	CcSEcCtD
Crizotinib—Body temperature increased—Dexamethasone—rheumatoid arthritis	3.58e-05	0.000857	CcSEcCtD
Crizotinib—Asthenia—Methylprednisolone—rheumatoid arthritis	3.57e-05	0.000855	CcSEcCtD
Crizotinib—Nausea—Cyclosporine—rheumatoid arthritis	3.54e-05	0.000848	CcSEcCtD
Crizotinib—Paraesthesia—Prednisone—rheumatoid arthritis	3.54e-05	0.000848	CcSEcCtD
Crizotinib—TESK1—Dexamethasone—Prednisone—rheumatoid arthritis	3.51e-05	0.026	CbGdCrCtD
Crizotinib—TESK1—Betamethasone—Prednisone—rheumatoid arthritis	3.51e-05	0.026	CbGdCrCtD
Crizotinib—Dizziness—Hydrocortisone—rheumatoid arthritis	3.5e-05	0.000839	CcSEcCtD
Crizotinib—CYP3A4—digestive system—rheumatoid arthritis	3.47e-05	0.000904	CbGeAlD
Crizotinib—Dyspepsia—Prednisone—rheumatoid arthritis	3.47e-05	0.000831	CcSEcCtD
Crizotinib—TESK1—Dexamethasone—Prednisolone—rheumatoid arthritis	3.43e-05	0.0254	CbGdCrCtD
Crizotinib—TESK1—Betamethasone—Prednisolone—rheumatoid arthritis	3.43e-05	0.0254	CbGdCrCtD
Crizotinib—Decreased appetite—Prednisone—rheumatoid arthritis	3.42e-05	0.00082	CcSEcCtD
Crizotinib—Rash—Prednisolone—rheumatoid arthritis	3.42e-05	0.000819	CcSEcCtD
Crizotinib—Dermatitis—Prednisolone—rheumatoid arthritis	3.42e-05	0.000818	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—rheumatoid arthritis	3.41e-05	0.000817	CcSEcCtD
Crizotinib—Diarrhoea—Methylprednisolone—rheumatoid arthritis	3.4e-05	0.000815	CcSEcCtD
Crizotinib—Fatigue—Prednisone—rheumatoid arthritis	3.4e-05	0.000814	CcSEcCtD
Crizotinib—Constipation—Prednisone—rheumatoid arthritis	3.37e-05	0.000807	CcSEcCtD
Crizotinib—Vomiting—Hydrocortisone—rheumatoid arthritis	3.37e-05	0.000807	CcSEcCtD
Crizotinib—Rash—Hydrocortisone—rheumatoid arthritis	3.34e-05	0.0008	CcSEcCtD
Crizotinib—Dermatitis—Hydrocortisone—rheumatoid arthritis	3.34e-05	0.000799	CcSEcCtD
Crizotinib—Dizziness—Triamcinolone—rheumatoid arthritis	3.3e-05	0.00079	CcSEcCtD
Crizotinib—Dizziness—Methylprednisolone—rheumatoid arthritis	3.29e-05	0.000788	CcSEcCtD
Crizotinib—Infection—Methotrexate—rheumatoid arthritis	3.27e-05	0.000784	CcSEcCtD
Crizotinib—Asthenia—Betamethasone—rheumatoid arthritis	3.25e-05	0.000778	CcSEcCtD
Crizotinib—Asthenia—Dexamethasone—rheumatoid arthritis	3.25e-05	0.000778	CcSEcCtD
Crizotinib—Nervous system disorder—Methotrexate—rheumatoid arthritis	3.23e-05	0.000774	CcSEcCtD
Crizotinib—Nausea—Prednisolone—rheumatoid arthritis	3.22e-05	0.000772	CcSEcCtD
Crizotinib—Skin disorder—Methotrexate—rheumatoid arthritis	3.2e-05	0.000766	CcSEcCtD
Crizotinib—Vomiting—Triamcinolone—rheumatoid arthritis	3.17e-05	0.000759	CcSEcCtD
Crizotinib—Vomiting—Methylprednisolone—rheumatoid arthritis	3.16e-05	0.000758	CcSEcCtD
Crizotinib—Nausea—Hydrocortisone—rheumatoid arthritis	3.15e-05	0.000753	CcSEcCtD
Crizotinib—Rash—Triamcinolone—rheumatoid arthritis	3.14e-05	0.000753	CcSEcCtD
Crizotinib—Dermatitis—Triamcinolone—rheumatoid arthritis	3.14e-05	0.000752	CcSEcCtD
Crizotinib—Rash—Methylprednisolone—rheumatoid arthritis	3.14e-05	0.000751	CcSEcCtD
Crizotinib—Dermatitis—Methylprednisolone—rheumatoid arthritis	3.13e-05	0.000751	CcSEcCtD
Crizotinib—Body temperature increased—Prednisone—rheumatoid arthritis	3.11e-05	0.000746	CcSEcCtD
Crizotinib—Diarrhoea—Dexamethasone—rheumatoid arthritis	3.1e-05	0.000742	CcSEcCtD
Crizotinib—Diarrhoea—Betamethasone—rheumatoid arthritis	3.1e-05	0.000742	CcSEcCtD
Crizotinib—Dizziness—Betamethasone—rheumatoid arthritis	2.99e-05	0.000717	CcSEcCtD
Crizotinib—Dizziness—Dexamethasone—rheumatoid arthritis	2.99e-05	0.000717	CcSEcCtD
Crizotinib—Nausea—Triamcinolone—rheumatoid arthritis	2.96e-05	0.000709	CcSEcCtD
Crizotinib—Paraesthesia—Methotrexate—rheumatoid arthritis	2.96e-05	0.000708	CcSEcCtD
Crizotinib—Nausea—Methylprednisolone—rheumatoid arthritis	2.95e-05	0.000708	CcSEcCtD
Crizotinib—Dyspnoea—Methotrexate—rheumatoid arthritis	2.94e-05	0.000703	CcSEcCtD
Crizotinib—Dyspepsia—Methotrexate—rheumatoid arthritis	2.9e-05	0.000694	CcSEcCtD
Crizotinib—Vomiting—Dexamethasone—rheumatoid arthritis	2.88e-05	0.000689	CcSEcCtD
Crizotinib—Vomiting—Betamethasone—rheumatoid arthritis	2.88e-05	0.000689	CcSEcCtD
Crizotinib—Decreased appetite—Methotrexate—rheumatoid arthritis	2.86e-05	0.000686	CcSEcCtD
Crizotinib—Rash—Dexamethasone—rheumatoid arthritis	2.85e-05	0.000683	CcSEcCtD
Crizotinib—Rash—Betamethasone—rheumatoid arthritis	2.85e-05	0.000683	CcSEcCtD
Crizotinib—Dermatitis—Dexamethasone—rheumatoid arthritis	2.85e-05	0.000683	CcSEcCtD
Crizotinib—Dermatitis—Betamethasone—rheumatoid arthritis	2.85e-05	0.000683	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Methotrexate—rheumatoid arthritis	2.84e-05	0.000681	CcSEcCtD
Crizotinib—Fatigue—Methotrexate—rheumatoid arthritis	2.84e-05	0.00068	CcSEcCtD
Crizotinib—Asthenia—Prednisone—rheumatoid arthritis	2.83e-05	0.000677	CcSEcCtD
Crizotinib—Diarrhoea—Prednisone—rheumatoid arthritis	2.7e-05	0.000646	CcSEcCtD
Crizotinib—Nausea—Betamethasone—rheumatoid arthritis	2.69e-05	0.000644	CcSEcCtD
Crizotinib—Nausea—Dexamethasone—rheumatoid arthritis	2.69e-05	0.000644	CcSEcCtD
Crizotinib—Dizziness—Prednisone—rheumatoid arthritis	2.61e-05	0.000624	CcSEcCtD
Crizotinib—Body temperature increased—Methotrexate—rheumatoid arthritis	2.6e-05	0.000624	CcSEcCtD
Crizotinib—Vomiting—Prednisone—rheumatoid arthritis	2.5e-05	0.0006	CcSEcCtD
Crizotinib—ABCB1—lymphoid tissue—rheumatoid arthritis	2.49e-05	0.000648	CbGeAlD
Crizotinib—Rash—Prednisone—rheumatoid arthritis	2.48e-05	0.000595	CcSEcCtD
Crizotinib—Dermatitis—Prednisone—rheumatoid arthritis	2.48e-05	0.000595	CcSEcCtD
Crizotinib—ABCB1—digestive system—rheumatoid arthritis	2.46e-05	0.00064	CbGeAlD
Crizotinib—Asthenia—Methotrexate—rheumatoid arthritis	2.36e-05	0.000566	CcSEcCtD
Crizotinib—Nausea—Prednisone—rheumatoid arthritis	2.34e-05	0.000561	CcSEcCtD
Crizotinib—Diarrhoea—Methotrexate—rheumatoid arthritis	2.25e-05	0.00054	CcSEcCtD
Crizotinib—Dizziness—Methotrexate—rheumatoid arthritis	2.18e-05	0.000522	CcSEcCtD
Crizotinib—Vomiting—Methotrexate—rheumatoid arthritis	2.09e-05	0.000502	CcSEcCtD
Crizotinib—Rash—Methotrexate—rheumatoid arthritis	2.08e-05	0.000497	CcSEcCtD
Crizotinib—Dermatitis—Methotrexate—rheumatoid arthritis	2.07e-05	0.000497	CcSEcCtD
Crizotinib—Nausea—Methotrexate—rheumatoid arthritis	1.96e-05	0.000469	CcSEcCtD
Crizotinib—JAK2—Immune System—CD4—rheumatoid arthritis	4.32e-07	4.45e-06	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—MAPK8—rheumatoid arthritis	4.32e-07	4.45e-06	CbGpPWpGaD
Crizotinib—LYN—Innate Immune System—IL6—rheumatoid arthritis	4.29e-07	4.42e-06	CbGpPWpGaD
Crizotinib—ABL1—Innate Immune System—IL6—rheumatoid arthritis	4.27e-07	4.4e-06	CbGpPWpGaD
Crizotinib—PTK2B—Immune System—IL6—rheumatoid arthritis	4.26e-07	4.4e-06	CbGpPWpGaD
Crizotinib—LCK—Hemostasis—TP53—rheumatoid arthritis	4.26e-07	4.4e-06	CbGpPWpGaD
Crizotinib—LYN—Immune System—IL1B—rheumatoid arthritis	4.26e-07	4.4e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CSF2—rheumatoid arthritis	4.26e-07	4.39e-06	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—MMP9—rheumatoid arthritis	4.25e-07	4.38e-06	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—IL6—rheumatoid arthritis	4.25e-07	4.38e-06	CbGpPWpGaD
Crizotinib—LYN—Immune System—IL2—rheumatoid arthritis	4.25e-07	4.38e-06	CbGpPWpGaD
Crizotinib—ABL1—Immune System—IL1B—rheumatoid arthritis	4.24e-07	4.37e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—IL6R—rheumatoid arthritis	4.24e-07	4.37e-06	CbGpPWpGaD
Crizotinib—ABL1—Immune System—IL2—rheumatoid arthritis	4.23e-07	4.36e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—IL6ST—rheumatoid arthritis	4.21e-07	4.34e-06	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—NFKB1—rheumatoid arthritis	4.2e-07	4.33e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—TYK2—rheumatoid arthritis	4.2e-07	4.33e-06	CbGpPWpGaD
Crizotinib—CDK7—Disease—IL6—rheumatoid arthritis	4.19e-07	4.32e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—TYK2—rheumatoid arthritis	4.18e-07	4.31e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—NOS2—rheumatoid arthritis	4.18e-07	4.3e-06	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—TGFB1—rheumatoid arthritis	4.16e-07	4.29e-06	CbGpPWpGaD
Crizotinib—BLK—Immune System—IL6—rheumatoid arthritis	4.16e-07	4.29e-06	CbGpPWpGaD
Crizotinib—FGR—Immune System—IL6—rheumatoid arthritis	4.15e-07	4.28e-06	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—MAPK8—rheumatoid arthritis	4.13e-07	4.26e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—NOS3—rheumatoid arthritis	4.12e-07	4.25e-06	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—MMP9—rheumatoid arthritis	4.12e-07	4.25e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—FN1—rheumatoid arthritis	4.08e-07	4.2e-06	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—NFKB1—rheumatoid arthritis	4.08e-07	4.2e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—IL6R—rheumatoid arthritis	4.07e-07	4.19e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—IL6ST—rheumatoid arthritis	4.06e-07	4.19e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—MMP3—rheumatoid arthritis	4.06e-07	4.18e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—CD80—rheumatoid arthritis	4.05e-07	4.18e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—LEP—rheumatoid arthritis	4.05e-07	4.17e-06	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—VEGFA—rheumatoid arthritis	4.04e-07	4.17e-06	CbGpPWpGaD
Crizotinib—JAK2—Innate Immune System—IL6—rheumatoid arthritis	4.01e-07	4.14e-06	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—MAPK8—rheumatoid arthritis	4.01e-07	4.13e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—SPP1—rheumatoid arthritis	4e-07	4.13e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—NOS3—rheumatoid arthritis	4e-07	4.12e-06	CbGpPWpGaD
Crizotinib—JAK2—Immune System—IL1B—rheumatoid arthritis	3.99e-07	4.11e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—CD4—rheumatoid arthritis	3.99e-07	4.11e-06	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—VEGFA—rheumatoid arthritis	3.99e-07	4.11e-06	CbGpPWpGaD
Crizotinib—LYN—Immune System—NFKB1—rheumatoid arthritis	3.98e-07	4.1e-06	CbGpPWpGaD
Crizotinib—JAK2—Immune System—IL2—rheumatoid arthritis	3.97e-07	4.1e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—ENO1—rheumatoid arthritis	3.97e-07	4.09e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—PTGS2—rheumatoid arthritis	3.96e-07	4.08e-06	CbGpPWpGaD
Crizotinib—ABL1—Immune System—NFKB1—rheumatoid arthritis	3.96e-07	4.08e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—IFNG—rheumatoid arthritis	3.92e-07	4.04e-06	CbGpPWpGaD
Crizotinib—LYN—Immune System—MAPK8—rheumatoid arthritis	3.91e-07	4.03e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—CD80—rheumatoid arthritis	3.91e-07	4.03e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—CXCL8—rheumatoid arthritis	3.91e-07	4.03e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—PTK2—rheumatoid arthritis	3.9e-07	4.02e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CCR5—rheumatoid arthritis	3.9e-07	4.02e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—MED1—rheumatoid arthritis	3.89e-07	4.01e-06	CbGpPWpGaD
Crizotinib—ABL1—Immune System—MAPK8—rheumatoid arthritis	3.89e-07	4.01e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—TYK2—rheumatoid arthritis	3.86e-07	3.98e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—CXCL8—rheumatoid arthritis	3.85e-07	3.97e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—IL2RA—rheumatoid arthritis	3.84e-07	3.96e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CCL5—rheumatoid arthritis	3.83e-07	3.95e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—FN1—rheumatoid arthritis	3.82e-07	3.93e-06	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—VEGFA—rheumatoid arthritis	3.81e-07	3.93e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—C3—rheumatoid arthritis	3.81e-07	3.92e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—IL6ST—rheumatoid arthritis	3.8e-07	3.92e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—NOS3—rheumatoid arthritis	3.79e-07	3.91e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—CAT—rheumatoid arthritis	3.79e-07	3.9e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—CD4—rheumatoid arthritis	3.78e-07	3.9e-06	CbGpPWpGaD
Crizotinib—TYK2—Disease—TGFB1—rheumatoid arthritis	3.78e-07	3.89e-06	CbGpPWpGaD
Crizotinib—SRC—Hemostasis—TP53—rheumatoid arthritis	3.77e-07	3.89e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CSF2—rheumatoid arthritis	3.77e-07	3.89e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—IL6R—rheumatoid arthritis	3.75e-07	3.87e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—IL2—rheumatoid arthritis	3.73e-07	3.85e-06	CbGpPWpGaD
Crizotinib—JAK2—Immune System—NFKB1—rheumatoid arthritis	3.72e-07	3.84e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—POMC—rheumatoid arthritis	3.71e-07	3.83e-06	CbGpPWpGaD
Crizotinib—ABCB1—Transmembrane transport of small molecules—ALB—rheumatoid arthritis	3.71e-07	3.83e-06	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—TGFB1—rheumatoid arthritis	3.71e-07	3.83e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—TYK2—rheumatoid arthritis	3.7e-07	3.82e-06	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—VEGFA—rheumatoid arthritis	3.7e-07	3.81e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—IL2—rheumatoid arthritis	3.68e-07	3.8e-06	CbGpPWpGaD
Crizotinib—JAK2—Immune System—MAPK8—rheumatoid arthritis	3.66e-07	3.77e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CD80—rheumatoid arthritis	3.66e-07	3.77e-06	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—TGFB1—rheumatoid arthritis	3.66e-07	3.77e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—CXCL8—rheumatoid arthritis	3.65e-07	3.77e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—CCL2—rheumatoid arthritis	3.63e-07	3.75e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—IL6R—rheumatoid arthritis	3.62e-07	3.74e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—ACP5—rheumatoid arthritis	3.62e-07	3.73e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—B3GNT2—rheumatoid arthritis	3.62e-07	3.73e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—CXCL8—rheumatoid arthritis	3.55e-07	3.66e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—SPP1—rheumatoid arthritis	3.55e-07	3.65e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—LEP—rheumatoid arthritis	3.54e-07	3.65e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—MMP9—rheumatoid arthritis	3.53e-07	3.64e-06	CbGpPWpGaD
Crizotinib—SRC—Developmental Biology—IL6—rheumatoid arthritis	3.52e-07	3.63e-06	CbGpPWpGaD
Crizotinib—LCK—Innate Immune System—IL6—rheumatoid arthritis	3.51e-07	3.62e-06	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—TGFB1—rheumatoid arthritis	3.5e-07	3.61e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—NFKB1—rheumatoid arthritis	3.5e-07	3.6e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—IL1B—rheumatoid arthritis	3.49e-07	3.6e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—CD4—rheumatoid arthritis	3.49e-07	3.6e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—IL2—rheumatoid arthritis	3.49e-07	3.6e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—MMP9—rheumatoid arthritis	3.49e-07	3.59e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—IL2—rheumatoid arthritis	3.48e-07	3.59e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—POMC—rheumatoid arthritis	3.48e-07	3.58e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—IFNG—rheumatoid arthritis	3.47e-07	3.58e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—PTGS2—rheumatoid arthritis	3.47e-07	3.58e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CCR5—rheumatoid arthritis	3.45e-07	3.56e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—NFKB1—rheumatoid arthritis	3.45e-07	3.56e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—MAPK8—rheumatoid arthritis	3.44e-07	3.54e-06	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—TP53—rheumatoid arthritis	3.43e-07	3.53e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—TYK2—rheumatoid arthritis	3.42e-07	3.53e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CCL2—rheumatoid arthritis	3.4e-07	3.51e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—IL2RA—rheumatoid arthritis	3.4e-07	3.5e-06	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—TGFB1—rheumatoid arthritis	3.4e-07	3.5e-06	CbGpPWpGaD
Crizotinib—PTK2—Immune System—IL6—rheumatoid arthritis	3.39e-07	3.5e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—IL6R—rheumatoid arthritis	3.39e-07	3.5e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—IL2—rheumatoid arthritis	3.39e-07	3.5e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—MAPK8—rheumatoid arthritis	3.39e-07	3.49e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling by GPCR—IL6—rheumatoid arthritis	3.37e-07	3.48e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—C3—rheumatoid arthritis	3.37e-07	3.47e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—NOS3—rheumatoid arthritis	3.36e-07	3.46e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—CD4—rheumatoid arthritis	3.35e-07	3.45e-06	CbGpPWpGaD
Crizotinib—YES1—Immune System—IL6—rheumatoid arthritis	3.35e-07	3.45e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—FN1—rheumatoid arthritis	3.34e-07	3.45e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—IL6ST—rheumatoid arthritis	3.33e-07	3.43e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—MMP9—rheumatoid arthritis	3.31e-07	3.41e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—TYK2—rheumatoid arthritis	3.3e-07	3.4e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—NFKB1—rheumatoid arthritis	3.27e-07	3.37e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—NFKB1—rheumatoid arthritis	3.26e-07	3.36e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—BGN—rheumatoid arthritis	3.26e-07	3.36e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—NOS3—rheumatoid arthritis	3.24e-07	3.34e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—MAPK8—rheumatoid arthritis	3.22e-07	3.31e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—MMP9—rheumatoid arthritis	3.21e-07	3.31e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—MAPK8—rheumatoid arthritis	3.2e-07	3.3e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CD80—rheumatoid arthritis	3.2e-07	3.3e-06	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—IL6—rheumatoid arthritis	3.18e-07	3.27e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—NFKB1—rheumatoid arthritis	3.18e-07	3.27e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—VEGFA—rheumatoid arthritis	3.17e-07	3.27e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—MTHFR—rheumatoid arthritis	3.16e-07	3.26e-06	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—IL6—rheumatoid arthritis	3.14e-07	3.24e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—LEP—rheumatoid arthritis	3.14e-07	3.23e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—VEGFA—rheumatoid arthritis	3.13e-07	3.23e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—MAPK8—rheumatoid arthritis	3.12e-07	3.22e-06	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—IL6—rheumatoid arthritis	3.11e-07	3.21e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—IL1B—rheumatoid arthritis	3.09e-07	3.19e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—CD4—rheumatoid arthritis	3.09e-07	3.19e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—TYK2—rheumatoid arthritis	3.09e-07	3.18e-06	CbGpPWpGaD
Crizotinib—TYK2—Immune System—IL6—rheumatoid arthritis	3.08e-07	3.18e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—IL2—rheumatoid arthritis	3.08e-07	3.18e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—PTGS2—rheumatoid arthritis	3.07e-07	3.16e-06	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—TP53—rheumatoid arthritis	3.06e-07	3.15e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—POMC—rheumatoid arthritis	3.04e-07	3.14e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—NOS3—rheumatoid arthritis	3.03e-07	3.13e-06	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—TP53—rheumatoid arthritis	3.01e-07	3.1e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—ALOX5—rheumatoid arthritis	3e-07	3.09e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CCL2—rheumatoid arthritis	2.98e-07	3.07e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—IL6R—rheumatoid arthritis	2.97e-07	3.06e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—VEGFA—rheumatoid arthritis	2.97e-07	3.06e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—FN1—rheumatoid arthritis	2.96e-07	3.05e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—IL6ST—rheumatoid arthritis	2.95e-07	3.04e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—TGFB1—rheumatoid arthritis	2.91e-07	3e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—NFKB1—rheumatoid arthritis	2.89e-07	2.98e-06	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—TP53—rheumatoid arthritis	2.88e-07	2.97e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—VEGFA—rheumatoid arthritis	2.88e-07	2.97e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—CXCL8—rheumatoid arthritis	2.87e-07	2.96e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—TGFB1—rheumatoid arthritis	2.87e-07	2.96e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—TGFB1—rheumatoid arthritis	2.86e-07	2.95e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—CAT—rheumatoid arthritis	2.86e-07	2.95e-06	CbGpPWpGaD
Crizotinib—TYK2—Disease—IL6—rheumatoid arthritis	2.85e-07	2.93e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—MAPK8—rheumatoid arthritis	2.84e-07	2.92e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CD80—rheumatoid arthritis	2.84e-07	2.92e-06	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—IL6—rheumatoid arthritis	2.8e-07	2.88e-06	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—TP53—rheumatoid arthritis	2.8e-07	2.88e-06	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—IL6—rheumatoid arthritis	2.76e-07	2.84e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—IL2—rheumatoid arthritis	2.75e-07	2.83e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—TGFB1—rheumatoid arthritis	2.72e-07	2.81e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—TYK2—rheumatoid arthritis	2.71e-07	2.79e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—POMC—rheumatoid arthritis	2.7e-07	2.78e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CXCL8—rheumatoid arthritis	2.69e-07	2.77e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—NOS3—rheumatoid arthritis	2.66e-07	2.74e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—TGFB1—rheumatoid arthritis	2.65e-07	2.73e-06	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—IL6—rheumatoid arthritis	2.64e-07	2.72e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CCL2—rheumatoid arthritis	2.64e-07	2.72e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—IL6R—rheumatoid arthritis	2.63e-07	2.71e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—MMP9—rheumatoid arthritis	2.6e-07	2.68e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—NFKB1—rheumatoid arthritis	2.57e-07	2.65e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—IL2—rheumatoid arthritis	2.57e-07	2.65e-06	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—IL6—rheumatoid arthritis	2.56e-07	2.64e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—IL6—rheumatoid arthritis	2.56e-07	2.64e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—MAPK8—rheumatoid arthritis	2.53e-07	2.61e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—POMC—rheumatoid arthritis	2.53e-07	2.61e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—TGFB1—rheumatoid arthritis	2.51e-07	2.58e-06	CbGpPWpGaD
Crizotinib—LYN—Immune System—IL6—rheumatoid arthritis	2.5e-07	2.57e-06	CbGpPWpGaD
Crizotinib—ABL1—Immune System—IL6—rheumatoid arthritis	2.48e-07	2.56e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—ENO1—rheumatoid arthritis	2.45e-07	2.52e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—MMP9—rheumatoid arthritis	2.43e-07	2.51e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—NFKB1—rheumatoid arthritis	2.41e-07	2.48e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—TP53—rheumatoid arthritis	2.4e-07	2.47e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—TYK2—rheumatoid arthritis	2.39e-07	2.47e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—MTHFR—rheumatoid arthritis	2.38e-07	2.46e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—MAPK8—rheumatoid arthritis	2.37e-07	2.44e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—TP53—rheumatoid arthritis	2.36e-07	2.44e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CXCL8—rheumatoid arthritis	2.36e-07	2.43e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—NOS3—rheumatoid arthritis	2.35e-07	2.42e-06	CbGpPWpGaD
Crizotinib—JAK2—Immune System—IL6—rheumatoid arthritis	2.34e-07	2.41e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—VEGFA—rheumatoid arthritis	2.33e-07	2.41e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—ALB—rheumatoid arthritis	2.3e-07	2.38e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—IL2—rheumatoid arthritis	2.25e-07	2.32e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—TP53—rheumatoid arthritis	2.24e-07	2.31e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—TGFB1—rheumatoid arthritis	2.22e-07	2.29e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—NOS3—rheumatoid arthritis	2.2e-07	2.27e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—IL6—rheumatoid arthritis	2.19e-07	2.26e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—VEGFA—rheumatoid arthritis	2.18e-07	2.25e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—TP53—rheumatoid arthritis	2.18e-07	2.24e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—IL6—rheumatoid arthritis	2.16e-07	2.23e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—IL6—rheumatoid arthritis	2.16e-07	2.22e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—TGFB1—rheumatoid arthritis	2.14e-07	2.21e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—MMP9—rheumatoid arthritis	2.13e-07	2.2e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—NFKB1—rheumatoid arthritis	2.11e-07	2.17e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CXCL8—rheumatoid arthritis	2.09e-07	2.15e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—MAPK8—rheumatoid arthritis	2.07e-07	2.14e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—IL6—rheumatoid arthritis	2.05e-07	2.12e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—IL6—rheumatoid arthritis	2.05e-07	2.11e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—PTGS2—rheumatoid arthritis	2.02e-07	2.08e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—TGFB1—rheumatoid arthritis	2e-07	2.07e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—IL6—rheumatoid arthritis	1.99e-07	2.05e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—IL2—rheumatoid arthritis	1.99e-07	2.05e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—VEGFA—rheumatoid arthritis	1.91e-07	1.97e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—POMC—rheumatoid arthritis	1.91e-07	1.97e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—IL6—rheumatoid arthritis	1.89e-07	1.95e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—MMP9—rheumatoid arthritis	1.89e-07	1.94e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—NFKB1—rheumatoid arthritis	1.87e-07	1.92e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—MAPK8—rheumatoid arthritis	1.83e-07	1.89e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—IL6—rheumatoid arthritis	1.81e-07	1.87e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—TP53—rheumatoid arthritis	1.76e-07	1.82e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—CAT—rheumatoid arthritis	1.76e-07	1.81e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—TGFB1—rheumatoid arthritis	1.76e-07	1.81e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—ALB—rheumatoid arthritis	1.74e-07	1.79e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—VEGFA—rheumatoid arthritis	1.69e-07	1.75e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—IL6—rheumatoid arthritis	1.67e-07	1.72e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—NOS3—rheumatoid arthritis	1.66e-07	1.71e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—TP53—rheumatoid arthritis	1.65e-07	1.7e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—IL6—rheumatoid arthritis	1.61e-07	1.66e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—TGFB1—rheumatoid arthritis	1.55e-07	1.6e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PTGS2—rheumatoid arthritis	1.52e-07	1.57e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—IL6—rheumatoid arthritis	1.51e-07	1.56e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—MTHFR—rheumatoid arthritis	1.47e-07	1.51e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—TP53—rheumatoid arthritis	1.45e-07	1.49e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—IL6—rheumatoid arthritis	1.32e-07	1.36e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—TP53—rheumatoid arthritis	1.28e-07	1.32e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—POMC—rheumatoid arthritis	1.17e-07	1.21e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—IL6—rheumatoid arthritis	1.17e-07	1.21e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—ALB—rheumatoid arthritis	1.07e-07	1.1e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—NOS3—rheumatoid arthritis	1.02e-07	1.06e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PTGS2—rheumatoid arthritis	9.37e-08	9.66e-07	CbGpPWpGaD
